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Abstract
The use of dexamethasone in the management of bacterial menin
gitis in adults remains controversial. This report illustrates the case
of a 27-year-old male with severe meningococcal meningitis and
meningococcemia who completely recoveredafter receiving antibi
otics and dexamethasone. In adults with suspected bacterial men
ingitis, especially in high risk cases, the adjunctive use of dexam
ethasone may be beneficial.
Case Report
The 27-year-old Indonesian fisherman presented with two days of
acute mental status change. He was healthy until he developed an
upper respiratory infection five days prior to admission. Three days
prior to admission, he had a temperature of 104.8F, occipital
headache, and vomiting. Two days prior to admission, he became
confused and was unable to recall his own name. His mental status
worsened and he had urinary incontinence, and was brought to The
Queen’s Medical Center.
On exam, his temperature was 101 .7F, blood pressure was 98/74,
pulse rate was 89/minute, respiratory rate was 16/minute, and
oxygen saturation was 98% on room air. He was obtunded. He
opened his eyes spontaneously, did not respond to verbal com
mands, and was able to localize pain stimulus. Neck exam showed
marked nuchal rigidity. Muscle tone was normal. Reflexes were
diminished. Skin had diffuse petechiae on the trunk, extremities,
palms, and soles.
Initial studies showed a hemoglobin of 16.4g/dL and hematocrit
of 52.8%, leukocyte count of 9,300/mm with 82% segmented
neutrophils, normal bands, 10% lymphocytes, and 7% monocytes,
and a platelet count of 5 8,000/mm3.Computed tomography scan of
the brain without contrast was normal. Lumbar puncture showed an
opening pressure of33cmH70.Cerebrospinal fluid (CSF) was grossly
hazy and xanthochromic. CSF leukocyte count was 12,300/mm
with 94% segmented neutrophils and 6% lymphocytes. No red cells
or glucose were detected. Protein was 333mg%. CSF Gram’s stain
showed 1+ gram-negative diplococci. CSF and blood cultures grew
Neisseria meningitidis, group C.
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In the emergency department, the patient’s mental status contin
ued to deteriorate. He was given ceftriaxone 2gm IV empirically. He
was admitted to the intensive care unit where he was intubated.
Within six hours after receiving of the first dose of ceftriaxone, he
was started on dexamethasone 10mg IV q6h for five days. The
ceftriaxone was replaced by penicillin G 3.5 million units q4h based
on culture and sensitivities for a total antibiotic regimen of ten days.
The patient’s fever resolved on hospital day one. On hospital day
four, he was able to open his eyes and follow commands. He was
extubated and was transferred to the medical floor the next day. He
continued to improve, platelet count normalized, and he was dis
charged from the hospital within three weeks with no sequelae.
Discussion
This case may illustrate the successful adjunctive use ofdexametha
sone in an adult with severe meningococcal meningitis. On admis
sion, the patient was managed for presumed bacterial meningitis.
His prognosis was deemed to be poor based on his deteriorating
mental status. Risk factors for death among those with a single
episode of community-acquired meningitis include age 60 years,
obtundation on admission, and seizures within the first 24 hours.
The patient’s initial studies suggested bacterial meningitis, and he
was started on antibiotics and dexamethasone.
During the last 15 years, despite advances in the management of
bacterial meningitis, including the introduction of third-generation
cephalosporins, there have been no significant reductions in the
overall mortality or in the incidence of long-term neurological
sequelae following bacterial meningitis.7Bacterial meningitis con
tinues to be associated with high morbidity and mortality. In North
America, the case fatality rate for bacterial meningitis by pathogen
is: Streptococcus pneumoniae 19-46%, N. meningitidis 3-17%,
Haemophilus influenzae 3-11%, and Listeria monocytogenes 15-
40%.’
Because evidence from in-vitro studies, experimental animal
models, and clinical studies suggest that the host inflammatory
response is responsible for much of the serious sequelae of this
disease, there is interest in the adjunctive use of antiinflammatory
agents in the management of bacterial meningitis. The role for
corticosteriods in treating bacterial meningitis may include inhibit
ing the expression of mRNA for tumor necrosis factor (TNF) and
interleukin- 1 (IL- 1), the production of phospholipid derivatives
such as prostaglandins and platelet activating factor, the comple
ment activation, and the activity of the inducible nitric oxide
synthetase.7Although clinical trials support the use ofcorticosteriods
in children with bacterial meningitis, especially in those with H.
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influenzae type b,’3 there are few data supporting its use in adults.
In 1988, Label et al first reported that the use of dexamethasone
was associated with protection against hearing loss in childhood H.
influenzae type b meningitis. It was recommended for routine use in
childhood H. meningitis in l994.
Since 1988, there has been only one trial involving the adjunctive
use of dexamethasone in adults with bacterial meningitis. In a
prospective, randomized trial involving 147 adults (13-years old)
and 282 children with bacterial meningitis. Girgis et al found
significant reduction in the case fatality rate and neurological
sequelae in patients receiving dexamethasone. The breakdown of
the 429 cases were: N. meningitidis 267, S. pneunofniae 106, and H.
influenzae 56. Dexamethasone was given at 8 mg TM ql2h to
patients <12-years old and at 12mg TM ql2h to patients 12-years
old for three days. starting with first dose of antibiotics. They found
a reduction in case fatality rate. Twenty (5 adults and 15 children) of
210 patients died among those who received dexamethasone, com
pared with 42(18 adults and 24 children)/2 19 died among those who
did not receive dexamethasone (p<O.Ol). The reduction in case
fatality rate was statistically significant only in patients with S.
pneumoniae meningitis, in which 7/52 patients receiving dexam
ethasone died compared with 22/54 patients not receiving dexam
ethasone died (p<O.OO2). They also found a reduction in neurologic
sequelae, ie. hearing impairment and paresis, in patients receiving
dexamethasone. This was also statistically significant only in pa
tients with S. pneumoniae meningitis, in which 0/45 surviving
patients receiving dexamethasone had severe hearing loss, com
pared with 4/32 patients not receiving dexamethasone had severe
hearing loss (p<O.O5). They found no significant difference between
those who did and did not receive dexamethasone for the time it took
them to become afebrile or to regain consciousness, or in the mean
admission and 24- to 36-hour CSF leukocyte count, glucose or
protein content.6
In a review of treatment of bacterial meningitis, Quagliarello and
Scheld recommended adjunctive dexamethasone therapy in chil
dren >2-months old who have bacterial meningitis, particularly
those thought to be infected with H. influenzae, ie. in children not
vaccinated against H. influenzae and those with CSF showing gram-
negative coccobacilli. They believed in a more limited use of
dexamethasone in adults with bacterial meningitis, especially to
those with a high concentration of bacteria in CSF, ie. those with
positive CSF Gram’s stain, and evidence of increased intracranial
pressure. For those children and adults, they recommended starting
dexamethasone at 0.15 mg/kg body weight IV q6h for four days with
or slightly before the first dose of antibiotics.2
While corticosteriods could theoretically reduce the penetration
of antibiotics into the central nervous system, there is no clinical
evidence to support this.7 In a meta-analysis of randomized clinical
trials since 1988 involving dexamethasone as an adjunctive therapy
in bacterial meningitis involving primarily children, McIntyre eta!
found that adverse effects from dexamethasone use was only signifi
cant for secondary fever, but not for delayed CSF sterilization, late
seizures, reactive arthritis, mortality or gastrointestinal tract bleed
ing.5 Furthermore, the empirical use of dexamethasone with antibi
otics for suspected bacterial meningitis in patients with aseptic
meningitis appears to be safe. In a retrospective analysis of 32
children with suspected bacterial meningitis, there were no adverse
effects associated with the use of dexamethasone even in those with
nonbacterial infections or positive viral cultures.7
Regarding the timing and duration of dexamethasone regimens,
Townsend and Scheld suggested starting it before or at the same time
as the start of antibiotics, since the synthesis of TNF and IL-l occur
after the antibiotic-induced lysis of bacteria and exposure of cell
surface components.7A meta-analysis of randomized clinical trials
by Mcintyre et al found that a two-day and four-day dexamethasone
regimen resulted in similar outcomes, and is associated with a lower
risk of gastrointestinal tract bleeding, and that a one-day regimen
may be ineffective.5
Conclusion
There are no uniform guidelines for the adjunctive use of dexam
ethasone in adult bacterial meningitis. Because of the benefits
demonstrated in childhood cases, and the potential benefits of
antiinflammatory agents, one may consider using dexamethasone in
adults with suspected bacterial meningitis, especially in high risk
cases. In this case, dexamethasone 10 mg IV q6h for five days was
started within six hours of initiating the antibiotic regimen in a
patient with presumed bacterial meningitis and deteriorating mental
status, and he recovered without sequelae.
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